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ORIGINAL ARTICLE
Mutant JAK3 phosphoproteomic profiling predicts synergism
between JAK3 inhibitors and MEK/BCL2 inhibitors for the
treatment of T-cell acute lymphoblastic leukemia
S Degryse1,2,8, CE de Bock1,2,8, S Demeyer1,2, I Govaerts1,2, S Bornschein1,2, D Verbeke1,2, K Jacobs1,2, S Binos3, DA Skerrett-Byrne4,5,
HC Murray4,5, NM Verrills4,5, P Van Vlierberghe6,7, J Cools1,2 and MD Dun4,5
Mutations in the interleukin-7 receptor (IL7R) or the Janus kinase 3 (JAK3) kinase occur frequently in T-cell acute lymphoblastic
leukemia (T-ALL) and both are able to drive cellular transformation and the development of T-ALL in mouse models. However, the
signal transduction pathways downstream of JAK3 mutations remain poorly characterized. Here we describe the phosphoproteome
downstream of the JAK3(L857Q)/(M511I) activating mutations in transformed Ba/F3 lymphocyte cells. Signaling pathways regulated
by JAK3 mutants were assessed following acute inhibition of JAK1/JAK3 using the JAK kinase inhibitors ruxolitinib or tofacitinib.
Comprehensive network interrogation using the phosphoproteomic signatures identified significant changes in pathways
regulating cell cycle, translation initiation, mitogen-activated protein kinase and phosphatidylinositol-4,5-bisphosphate 3-kinase
(PI3K)/AKT signaling, RNA metabolism, as well as epigenetic and apoptotic processes. Key regulatory proteins within pathways that
showed altered phosphorylation following JAK inhibition were targeted using selumetinib and trametinib (MEK), buparlisib (PI3K)
and ABT-199 (BCL2), and found to be synergistic in combination with JAK kinase inhibitors in primary T-ALL samples harboring JAK3
mutations. These data provide the first detailed molecular characterization of the downstream signaling pathways regulated by
JAK3 mutations and provide further understanding into the oncogenic processes regulated by constitutive kinase activation aiding
in the development of improved combinatorial treatment regimens.
Leukemia (2018) 32, 788–800; doi:10.1038/leu.2017.276
INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
leukemia that is common in children and adolescents. Long-term
childhood ALL survival rates have improved significantly following
refined chemotherapeutic treatment regimens; however, these are
associated with substantial acute and long-term side effects.1
Recently, Janus kinase 3 (JAK3) mutations were identified in 16%
of T-ALL cases2 and it is now known to be sufficient to drive T-ALL
development in mice using an in vivo bone marrow transplant
model.3 JAK3 is a non-receptor tyrosine kinase and functions in
class I cytokine receptor complexes through binding of the
common γ chain (IL2RG). JAK3 binds the IL2RG that forms
heterodimers with other receptors such as the IL7Rα chain, which
in turn binds JAK1. Under normal conditions, ligand binding to the
receptor complex activates cytokine signaling through coopera-
tive JAK1/JAK3 phosphorylation. In this active conformation, they
phosphorylate downstream targets including STAT5. In addition to
canonical STAT5 activation, increasing evidence shows that the
interleukins (ILs) can activate additional signaling pathways in
T-cells. For example, a phosphoproteomic approach following
5 min stimulation with IL2 and IL15 found recruitment and
phosphorylation of the SHC–GRB2–SOS complex at the cytokine
receptor which then activates the canonical mitogen-activated
protein kinase (MAPK) pathway.4 Likewise, very early work found
that IL7 stimulation leads to JAK3-mediated association and
phosphorylation of the p85 subunit of the PI3-kinase.5
The recent identification of activating JAK3 mutations in T-ALL
cases shows promising therapeutic potential.6–8 Indeed, small
molecules targeting JAK family members are in development or
are already in use for the treatment of several diseases which
could be repurposed for T-ALL.9 However, detailed functional
analysis of the different JAK3 mutations has found these have
different dependencies on members of the IL7R complex for their
ability to cause cellular transformation.3,10 For example the JAK3
(M511I) mutation requires the presence of both JAK1 and the
IL2RG for cellular transformation, whereas the JAK3(L857Q) can
also signal independent from the JAK1/IL2RG complex.3,10 There-
fore, the pathways activated downstream of different JAK3
mutations in additional to canonical STAT5 activation, may not
only differ from wild-type cytokine activation of JAK3, but also
between the different JAK3 mutations themselves. Hence, the
detailed molecular characterization of the oncogenic JAK3 path-
ways based on the exact mutation present will aid in the
development of improved treatment strategies.
Accordingly, we have used quantitative assessment of the
phosphorylation status of proteins downstream of mutant JAK3
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(L857Q) and JAK3(M511I) using transformed Ba/F3 cells treated
with the JAK1/JAK3-selective inhibitors ruxolitinib or tofacitinib, or
a vehicle control. Our data have mapped associations between
mutant JAK3 signaling and multiple components of the phospha-
tidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT and MAPK
pathways, as well as to critical components of the cell cycle
machinery, anti-apoptotic constituents, RNA metabolism and
epigenetic regulators.
MATERIALS AND METHODS
Expression plasmids
JAK3 mutant sequences were synthesized by GenScript (Piscataway, NJ,
USA). All constructs were cloned into the murine stem cell virus–green
fluorescent protein vectors.
Cell culture, virus production and retroviral transduction
Cell culture, virus production and retroviral transduction were performed
as previously described.3
Quantitative phosphoproteomics
Discovery. Three independent sets of Ba/F3 cells expressing mutant
human JAK3(L857Q) were cultured as described previously3 and treated
with 500 nM tofacitinib, ruxolitinib or dimethylsulfoxide for 90 min
(3 × biological). Cell pellets were prepared as previously described.11
Membranes were enriched by ultra-centrifugation12 and proteins dissolved
in v/v 6 M urea/2 M thiourea. Proteins were then reduced, alkylated and
digested as previously described.11 Lipids were precipitated from
membrane peptides using formic acid and quantitated (Qubit protein
assay kit, Thermo Fisher Scientific, Carlsbad, CA, USA). One hundred
micrograms of membrane and soluble peptides from each of the nine
samples were individually labeled using tandem mass tags (TMT-10plex
2 × kits, Thermo Fisher Scientific, Bremen DE, Germany) and mixed with a
1:1 ratio.13 Phosphopeptides were isolated from the proteome using
titanium dioxide and immobilized metal affinity chromatographybefore
offline hydrophilic interaction liquid chromatography (LC).14 LC tandem
mass spectrometry (MS/MS) was performed on 24 mono-phosphopeptide
enriched hydrophilic interaction LC fractions, 12 membrane and 12 soluble
enriched fractions, as well as multi-phosphorylated peptides enriched from
both using a Q-Exactive Plus hybrid quadrupole-Orbitrap MS system
(Thermo Fisher Scientific, Bremen, Germany) coupled to a Dionex Ultimate
3000RSLC nanoflow HPLC system (Thermo Fisher Scientific). Samples were
loaded onto an Acclaim PepMap100 C18 75 μm×20 mm trap column
(Thermo Fisher Scientific) for pre-concentration and online desalting.
Separation was then achieved using an EASY-Spray PepMap C18
75 μm×500 mm column (Thermo Fisher Scientific), employing a linear
gradient from 2 to 32% acetonitrile at 300 nl/min over 120 min. Q-Exactive
Plus MS System (Thermo Fisher Scientific) was operated in full MS/data-
dependent acquisition MS/MS mode (data-dependent acquisition). The
Orbitrap mass analyzer was used at a resolution of 70 000, to acquire full
MS with an m/z range of 390–1400, incorporating a target automatic gain
control value of 1e6 and maximum fill times of 50 ms. The 20 most intense
multiply charged precursors were selected for higher-energy collision
dissociation fragmentation with a normalized collisional energy of 32. MS/
MS fragments were measured at an Orbitrap resolution of 35 000 using an
automatic gain control target of 2e5 and maximum fill times of 110 ms.
Parallel reaction monitoring. Phosphopeptides were loaded onto an
Acclaim PepMap100 C18 75 μm×20 mm trap column (Thermo Fisher
Scientific) for pre-concentration and online desalting, then separated using
EASY-Spray PepMap C18 75 μm×250 mm column (Thermo Fisher
Scientific). An optimized stepped 82 min gradient was employed (5 to
22 to 35%). Each sample was run in data-dependent acquisition mode
(described above) to evaluate phosphopeptide enrichment efficiency
(93–97%) and loading. Parallel reaction monitoring (PRM) was performed
using optimized methods for collision energy, charge state and retention
times at a resolution of 17 500, automatic gain control of 2e5, maximum fill
times of 90 ms and 1.6 m/z isolation window.
Data analysis
Database searching of all.raw files was performed using Proteome
Discoverer 2.1 (Thermo Fisher Scientific). Mascot 2.2.3 and SEQUEST HT
were used to search against the Swiss_Prot, Uniprot_mouse database
(24910 sequences, downloaded 19 April 2016). Database searching
parameters included up to two missed cleavages, to allow for full tryptic
digestion, a precursor mass tolerance set to 10 p.p.m. and fragment mass
tolerance 0.02 Da. Cysteine carbamidomethylation was set as a fixed
modification while dynamic modifications included oxidation (M), phospho
(S/T), phospho (Y) and TMT6plex (modification designated for TMT10plex).
Interrogation of the corresponding reversed database was also performed
to evaluate the false discovery rate of peptide identification using
Percolator on the basis of q-values, which were estimated from the
Figure 1. Experimental workflow. Three independent sets of Ba/F3 cells expressing mutant human JAK3 (L857Q) were cultured and treated
with 500 nM tofacitinib, ruxolitinib or dimethylsulfoxide (DMSO) for 90 min (biological and technical replicates). Cells were digested with Typ/
Lys-C mix. Peptides from each of the nine samples were labeled using tandem mass tags (TMT-10plex, Thermo Fisher Scientific) and mixed 1:1.
Phosphopeptides were isolated and liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed using a Q-Exactive
Plus hybrid quadrupole-Orbitrap MS system (Thermo Fisher Scientific). Database searching of all.raw files was performed using
Proteome Discoverer 2.1 (Thermo Fisher Scientific). Mascot 2.2.3 and SEQUEST HT were used to search against the Swiss_Prot, Uniprot_mouse
database.
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target-decoy search approach. To filter out target peptide spectrum
matches over the decoy-peptide spectrum matches, a fixed false discovery
rate of 1% was set at the peptide level. The experimental workflow is
shown in Figure 1. PRM data files were processed with PD 2.1 to generate
spectral libraries and uploaded into Skyline (MacCoss Lab, University of
Washington), which was then used to identify peptide chromatogram
peaks. Peptide quantification was performed by quantifying area under the
curve of the MS2 extracted ion chromatogram within Skyline.15 Results
were normalized to the spiked-in heavy-labelled peptide to account for
variations in sample injection. MS raw data is available in the Massive
public repository (PXD007046).
In silico analysis of phosphosites abundance and pathway
prediction
Quantitative phosphoproteomic differences across treatments were
clustered by unique phosphosites (Cluster3, Stanford University, Palo Alto,
CA, USA) and examined using heatmaps (Java Treeview, Stanford
University) to visualize trends and consistency (as described16) in
phosphopeptide abundance across treatment groups. Ingenuity Pathway
Analysis software (version 8.8, Ingenuity Systems, Redwood City, CA, USA)
together with the Core Analysis function was used to identify pathways
regulated by the JAK3(L857Q) mutation.
Western blotting
Cells were lysed in cold lysis buffer containing 5 mM NA3VO4, protease
inhibitors (Complete, Roche, Bazel, Switzerland) and PhosSTOP (Roche).
The proteins were separated on NuPAGE NOVEX Bis-Tris 4 to 12% gels
(Invitrogen, Carlsbad, CA, USA). Western blot analysis was performed using
antibodies against JAK3 (Cell Signaling, Danvers, MA, USA 3775), phospho-
STAT5 (Y694) (Cell Signaling 9359); STAT5 (Invitrogen 335900), phospho-
RanBP3 (Cell Signaling 9380); phospho-4E-BP1 (Cell Signaling 2855);
pERK1/2 (Cell Signaling 9101), ERK1 (Santa Cruz, Dallas, TX, USA, Sc-93),
pMEK1/2 (Cell Signaling 9154), MEK1/2 (Cell Signaling 9126) and β-actin
(Sigma-Aldrich A1978); secondary antibodies were conjugated with
horseradish peroxidase (GE Healthcare, Chicago, IL, USA). Bands were
visualized using a cooled charge-coupled device camera (ImageQuant
LAS-4000; GE Healthcare).
Inhibitor treatment in Ba/F3 cells
Ba/F3 cells (www.dsmz.de) were cultured and transduced as described.3
Cells were confirmed mycoplasma negative. Ba/F3 cells were seeded in 96-
well plates (1x105 cells/ml) and treated with compound or vehicle
(dimethylsulfoxide). A quantitative evaluation of proliferation was done
after 24 h using ATPlite (PerkinElmer, Waltham, MA, USA) and measured on
the VICTOR X4 Reader (PerkinElmer).
Ex vivo treatment of primary T-ALL samples
The mutational background of T-ALL samples used in this work is shown in
Supplementary Table S1. All human T-ALL samples were collected with
informed patient consent and with approval of the UZ Leuven ethics
committee. T-ALL cells were expanded in vivo by injection in 8 weeks old
female NSG mice. After 2–3 months, human T-ALL cells were isolated from
the spleen, seeded in 96-well plates (5 × 105 cells/well) and incubated with
vehicle (dimethylsulfoxide) or inhibitor. Cell viability was assessed 48 h
after adding the compounds by using the Guava easyCyte Flow Cytometer
(Millipore, Overijse, Belgium). CompuSyn was used to calculate the
combination index (CI). All animal experiments were approved by the KU
Leuven ethics committee.
Annexin V/PI staining and flow cytometry analyses
For apoptosis staining the fluorescein isothiocyanate Annexin V apoptosis
detection kit with propidium iodide was used as per the manufacturer’s
instructions (Biolegend, Dedham, MA, USA). Briefly, 500 000 cells of each
condition were stained for 20 min. Staining cells were washed in 1 × in
phosphate-buffered saline and data were acquired on the MACSQuant VYB
flow cytometer (Miltenyi Biotec, Cambridge, MA, USA). For phospho-flow
analysis, cells were fixed with Inside Fix and permeabilisation buffer
(Miltenyi Biotec), and stained with an APC-labeled antibody against
phospho-STAT5 (eBioscience, San Diego, CA, USA). Cells were analyzed
using the FACSVerse (BD, Bedford, MA, USA). All FACS data analysis was
carried out using FlowJo sotware (Tree Star, Ashland, OR, USA).
In vivo drug treatment of primary T-ALL sample
Patient sample 389E was injected into the lateral tail vein of 28 female NSG
mice. Leukemia burden was assessed by hCD45+ staining in the peripheral
blood on day 19 post injection. Mice were ranked from highest to lowest
hCD45 and then sequentially placed in four treatment groups. Animal
weight distribution was also assessed to determine equivalence between
all groups. Ruxolitinib and ABT-199 were administered daily by oral gavage
for 14 consecutive days, vehicle was given as placebo. No preliminary data
were available to perform a statistical power analysis. The investigators
were not blinded to the treatment groups.
RESULTS
JAK3 pathway network enrichment analysis
To determine the signal transduction pathways downstream
mutant JAK3, Ba/F3 cells transformed by the JAK3(L857Q)
mutation (signaling partially independent from JAK1) were initially
screened using unbiased global quantitative phosphoproteomic
profiling. This approach simultaneously determined the identity,
phosphorylation status and relative abundance of proteins
isolated from three biological replicates following JAK1 inhibition
(ruxolitinib) or JAK3 inhibition (tofacitinib) (Figure 1). Deep
phosphoproteomic coverage was achieved by employing a
multidimensional strategy incorporating protein pre-fractionation
and sequential phosphopeptide enrichment techniques to enrich
for mono- and multi-phosphorylated peptides, coupled to
hydrophilic interaction LC, to reduce sample complexity before
high-resolution tandem MS. A total of 6036 unique proteins and
2070 unique phosphoproteins, associated with ~ 5400 unique
phosphorylation sites were quantitatively sequenced across all 9
samples (Figures 2a–c and Supplementary Table S2). Accurate site-
specific assignment of phosphorylation was achieved using
phosphoRS17 using a false discovery rate of 1% followed by
manual interrogation for all peptides that were significantly
altered after JAK inhibition. The ratio of phosphosites identified
were 82.5% serine: 14.9% threonine: 2.6% tyrosine.
Using a cutoff of log2 fold change 40.5 we identified 84
downregulated unique phosphorylation sites and 29 upregulated
phosphorylation sites following 90 min of JAK3 inhibition using
tofacitinib across biological and technical replicates (Figure 2d).
Similarly, treatment with ruxolitinib identified 86 downregulated
and 20 upregulated phosphorylation sites (Figure 2e). In both
instances, the phosphorylation of STAT5A at tyrosine Y694 was
significantly reduced by − 5.9- and − 3.5-fold following tofacitinib
or ruxolitinib treatment, respectively (Figure 2f), which was also
confirmed by western blotting (Figure 2g).
The spectral intensity for each unique phosphosite (reporter-
ion) within each phosphoprotein was averaged across biological
and technical replicates for each treatment and grouped. The
global phosphopeptide profile of JAK3 and JAK1 inhibition were
clustered into canonical and biological pathways (as described in
Materials and Methods, Figure 3). As expected, canonical Ingenuity
Pathway Analysis pathways associated with decreased phospho-
site abundance after both tofacitinib and ruxolitinib treatments
was linked to JAK/STAT signaling and also IL-22 signaling. This
cluster was also significantly enriched for proteins implicated in
14-3-3-mediated signaling (Figure 3, Cluster 2). Cluster 3 showed
increased phosphosite abundance after tofacitinib and ruxolitinib
treatments with a significant enrichment for proteins implicated
DNA methylation, transcriptional repression and ERK/MAPK
signaling pathways.
Of interest, cluster 1 and cluster 5 are associated with
pharmacological inhibition of JAK3 specifically. These clusters
are enriched for pathways involved in altered DNA Repair
mediated by the homologous recombination repair pathways,
multiple components of complementary apoptotic cascades such
as the cytolytic granzyme B pathway, the growth arrest and DNA
damage-inducible 45 (GADD45) pathway (Figure 3, Cluster 1) and
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also PI3K/AKT signaling and protein ubiquitination (Figure 3,
Cluster 5). These data show that specific inhibition of JAK1 or JAK3
may have slightly different effects on downstream signaling
pathway.
The global phosphopeptide list was then filtered to generate a
short list of significantly altered changes common to both
tofacitinib or ruxolitinib treatment (average ± 0.5 log2-fold
change/dimethylsulfoxide control) (Supplementary Table 3). This
stringent short list consisted of 84 and 48 unique phosphosites
decreasing or increasing in phosphorylation respectively after
both tofacitinib and ruxolitinib treatment. A heatmap showing
individual replicate values of phosphosite abundances compared
to control is presented in Figure 4a for each protein identified.
Within this list, four proteins had altered tyrosine phosphorylation,
STAT5(Y694) and ACTB(Y198) sites were decreased after inhibitor
treatment whilst PGRMC2(Y204) and MCM2(Y137) were increased
after inhibitor treatment. The remaining changes occurred on
serine and threonine residues. These proteins and their major
cellular functions are illustrated schematically in Figure 4b.
Proteins involved in RNA processing and chromatin remodeling
are directly regulated downstream of mutant JAK3 signaling
There were 18 proteins associated with RNA metabolism including
mRNA stability/processing, splicing and degradation some of
which have established roles in cancer (Figure 4b). De novo
phosphorylation of Threonine 7 (T7) of SF3B1 (splicing factor 3b,
subunit 1) increased upon inhibition of JAK3 mutant signaling.
This factor is important for anchoring the spliceosome to
precursor mRNA and is one of the most frequently mutated
genes in chronic lymphocytic leukemia.18–20 Serine 100 of RNMT
showed increased phosphorylation and this protein is important
in the coordination of mRNA capping and linked to cancer.21 In
addition to RNA metabolism, an unexpected link with several
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Figure 2. Quantitative phosphoproteomic analysis of mutant JAK3 L857Q Ba/F3 cells. (a) Venn diagram summary of results from experimental
workflow after mapping of all phospho-proteomic data across all experiments. (b and c) Distribution of quantitative phosphorylation changes
of tofacitinib/control and ruxolitinib/control. (d and e) Tofacitinb (500 nM) treatment resulted in 84 down- and 29 upregulated
phosphorylation sites (significance reported for changes versus control of ± 0.5 log2 fold). (e) Ruxolitinib (500 nM) treatment resulted in 86
down- and 20 upregulated phosphorylation sites (significance reported for changes versus control of ± 0.5 log2 fold). (f) STAT5A
showed consistent downregulation across all three replicates upon tofacitinib and ruxolitinib treatment in the phospho-proteomic screen.
(g) Western blot analysis further validated the decrease in phospho-STAT5 (Y694) upon treatment with JAK selective inhibitors tofacitinib
and ruxolitinib.
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proteins involved in epigenetic regulation was also found.
HIST1H1E, a regulator of higher-order chromatin structure that is
mutated in lymphoma,22 showed an increased phosphorylation
on serine 36 upon JAK inhibition. MCM8, which is linked with the
development of chronic myelogenous leukemia, showed a
decrease in phosphorylation upon JAK inhibition.23
Confirmation of novel phosphorylation changes in proteins
regulating RNA processing and chromatin remodeling was
performed by an independent targeted proteomics experiment
(parallel reaction monitoring, PRM) (Figures 4c–e and
Supplementary Table 2). This approach revealed a significant
level of correlation between methods of phosphopeptide
quantification (that is, discovery by data-dependent acquisition
and validation by PRM) and also between JAK3(L867Q) and JAK3
(M511I) mutants (Figures 4c and d). Reduction in relative fold-
change is a consequence of data-dependent acquisition based
quantitative approaches (reporter-ion based relative quantifica-
tion—TMT Figure 4a), owing to the thousands of events measured
across nine samples simultaneously.24 Therefore, changes in
phosphorylation in proteins such as STAT5 and YBX3 were more
accurately measured using targeted methods such as PRM
(Figure 4e). Nevertheless, discovery proteomics is a powerful tool
that guided our PRM validation study and revealed a highly
significant correlation between phosphoproteins regulating RNA
processing and chromatin remodeling in both JAK3 L857Q- and
M511I-transformed cells.
Human JAK3 mutant T-ALL samples 389E and XC65
(Supplementary Table 1) were also validated by PRM. Significant
correlation of the abundance of phosphoproteins regulated by
mutant JAK3 were seen between patients following JAK1
inhibition using ruxolitinib (Figure 4e and Supplementary
Figure 1A). STAT5 and proteins implicated in DNA methylation
(DNMT1 and KDM2A), genome replication (MCM8 and NCAPD2)
and pre-mRNA processing (SF1 and NCBP1) were significantly
modulated in both patient samples following JAK inhibition
(Figure 4e and Supplementary Table 2). However, regulation of
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Figure 4. Heatmap and schematic representation of phosphosites down- or upregulated common to both tofacitinib and ruxolitinib
treatment. Phosphosites with an average decrease or increase of 0.5 log2 fold relative to dimethylsulfoxide (DMSO) control are shown.
(a) Color reflects fold change in phosphorylation relative to control (DMSO treated) cells. Blue and yellow indicate down- and upregulation
respectively. An asterisk indicates phosphosites, which could not be annotated with 100% certainty. (b) Schematic for a selection of
phosphosites with an average decrease or increase of 0.5 log2 fold relative to DMSO control are shown alongside the main cellular process
they are involved. Yellow and blue indicates an increase or decrease in phosphorylation, respectively upon JAK selective inhibition (tofacitinib
and ruxolitinib). (c) PRM validation of phosphoproteomic profiling of JAK3(L857Q) signaling following tofacitinib or ruxolitinib treatment.
(d) PRM correlation between JAK3(L857Q) and JAK3(M511) signaling following tofacitinib and ruxolitinib treatment. (e) PRM validation of
phosphorylation upon JAK selective inhibition (tofacitinib and ruxolitinib) in BaF/3 JAK3(L857Q) and JAK3(M511I) transformed cells and in
patient samples 389E and XC65. (PRM phosphosite annotation reflects mouse residues), n/f denotes phosphopeptide not found.
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phosphoproteins following mutant JAK3 inhibition using tofaciti-
nib was not as consistent as with ruxolitinib, indicating again
differences between these drugs (Figure 4e).
To further complement the PRM, western blot analysis was used
to confirm the phosphorylation status for EIF4EBP1 at threonine
T45 and RANBP3 at serine S58, for which site-specific phospho-
antibodies were available. Both showed significantly reduced
phosphorylation following treatment with tofacitinib or ruxolitinib
(Supplementary Figure S1B). Moreover, these phosphorylation
sites were confirmed as being directly downstream of JAK3
(L857Q and M511I) mutations with Ba/F3 transformed by the
activating mutation STAT5 N642H or parental Ba/F3 stimulated
with IL3 showed significantly less phosphorylation at these sites
compared with untreated Ba/F3 cells expressing either of these
JAK3 mutations (Supplementary Figure S1B).
Inhibiting JAK in combination with the MAPK, PI3K and Bcl-2
pathway results in synergistic or additive effects on Ba/F3 cells
transformed by JAK3 mutants
Although a large number of novel phosphorylation changes were
identified downstream of mutant JAK3 signaling including in RNA
metabolism and chromatin remodeling, the majority of these
proteins remain difficult to target due to the lack of small
molecular inhibitors. To this end, pathway interrogation using
Ingenuity Pathway Analysis revealed multiple components of
MAPK, PI3K and apoptosis pathway to be modulated following
either tofacitinib or ruxolitinib treatment (Figure 5a,
Supplementary Figures S2–S4 and Supplementary Table S4).
Specifically, phosphorylation changes were seen in SHC, GRB2
and GAB1/2, which are upstream of the MEK/ERK pathway.
Moreover, GAB1/2 is also known to associate with the PI3K
pathway (Figure 5b). In line with this analysis, acute inhibition of
JAK3(L857Q)- and JAK3(M511I)-transformed Ba/F3 cells with
tofacitinib revealed significantly decreased pERK1/2 and pMEK1
levels. This was further reduced when given in combination with
the MEK inhibitors selumetinib and trametinib (Figure 5c).
Although the phosphoproteomics data did not identify phosphor-
ylation changes in any anti- or pro-apoptotic proteins, mutant
JAK3 signaling would be expected to upregulate members of the
anti-apoptotic BCL2 family including BCL-2 and MCL1 at the
transcriptional level.25 Analysis of expression data from 264 T-ALL
patients26 revealed that cases with JAK3 mutations (n= 20) had
significantly higher levels of BCL2 compared with non-mutated
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Figure 5. Ingenuity Pathway Analysis (IPA) identifies significant enrichment for PI3K/AKT, MEK/ERK and apoptosis signaling. (a) Pathways for
which phospho-sites showed a 0.5 log2 fold change increase or decrease in phosphorylation compared to control following tofacitinib or
ruxolitinib treatment are shown. (b) Schematic representation of PI3K, apoptosis, and MEK/ERK pathway. Proteins that show an increase or
decrease in phosphorylation by tofacitinib or ruxolitinib treatment (average ± 0.5 log2 fold change /dimethylsulfoxide (DMSO) control) are
indicated with an asterisk. Inhibitors used in downstream experiments are indicated. (c) Western blot assessment of downstream STAT5, ERK
and MEK activation in JAK3(L857Q) or JAK3(M511I) transformed Ba/F3 cells treated with tofacitinib, selumtinib or trametinib for 90 min.
(d) RNA-seq analysis of BCL2, MCL1 and BCL-XL in T-ALL patients that either have a JAK3 mutation (n= 20), other JAK-STAT pathway mutations
(n= 45, includes mutations in IL7R, PTPN2, FLT3, STAT5B, JAK1, JAK3, SH2B3, IL2RB) or no mutations in JAK-STAT (n= 199). (P-value calculated
using welch t-test).
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cases. There were no differences for BCL-XL or MCL1 expression
(Figure 5d).
These data therefore provided the rationale to test whether
selective inhibitors of these pathways such as the selective Bcl-2
inhibitor (ABT-199), PI3K inhibitor (buparlisib) or MEK inhibitors
(selmuetinib and trametinib) would synergistically inhibit cellular
growth and survival when used in combination with a JAK
selective inhibitor.
Ba/F3 cells transformed by two different JAK3 mutants, JAK3
(M511I) or JAK3(L857Q), were treated with a combination
of various concentrations of tofacitinib and the MEK
inhibitor selumetinib. Most combinations showed a
synergistic effect ranging from moderate (0.3–0.05 μM tofacitinib
and 0.89–1.582 μM selumetinib) to high synergism (0.3 μM
tofacitinib and 2.109–5 μM selumetinib) (Figure 6a).
Interestingly, all combinations of tofacitinib with the MEK inhibitor
trametinib showed synergistic cytotoxicity (CI o0.1–0.9) in a
dose-dependent manner (Figure 6a). This combination had
no effect on parental Ba/F3 cells stimulated by IL3 (data not
shown).
Inhibition of the anti-apoptotic protein Bcl-2 using ABT-199 in
combination with tofacitinib was also synergistic at moderate
concentrations. However, low concentrations of both tofacitinib
and ABT-199 were antagonistic, with CI values reaching 2.7. Effects
from intermediate concentration combinations vary from moder-
ate synergism to highly synergistic. The combination of 0.3 μM
ABT-199 and 0.3 μM tofacitinib induced synergistic cytotoxicity (CI
values up to 0.3).
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Figure 6. Inhibiting JAK in combination with the MAPK, PI3K and Bcl-2 pathway results in synergistic or additive effects on Ba/F3 cells
transformed by JAK3 mutants. (a) Chou-Talalay plots showing the effect of tofacitinib with MEK inhibitors (selumetinib, trametinib), Bcl-2
inhibitor (ABT-199) or PI3K inhibitor (buparlisib) on Ba/F3 cells transformed by JAK3 M511I or L857Q after 24 h incubation. CompuSyn was
used to calculate the combination index (CI). CIo1 indicate synergistic effects, C= 1 indicate additive effects, C41 indicate antagonistic
effects. (b) Ba/F3 transformed by M511I or L857Q were treated for 24 h with single compounds or combination. Relative proliferation
compared to vehicle treated cells is shown. Data represents the average of three experiments± s.e.m. Significance was calculated using One-
way analysis of variance (ANVA) and the Bonferroni correction. (****P⩽ 0.0001; ***P⩽ 0.001; **P⩽ 0.01). Concentrations used; 0.15 μM
tofacitinib in combination with 3.75 μM selumetinib, 0.67 μM trametinib, 0.6 μM buparlisib and 0.3 μM tofacitinib in combination with 0.15 μM
ABT-199.
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Figure 7. Synergistic effect of tofacitinib in combination with MEK or Bcl-2 inhibitors in JAK3 mutant PDX samples. (a) Schematic
representation of experimental workflow. (b) Chou-Talalay plots showing the effect of tofacitinib with MEK inhibitors (selumetinib, trametinib)
or Bcl-2 inhibitor (ABT-199) on T-ALL-derived PDX samples. CompuSyn was used to calculate the combination index (CI). CIo1 indicate
synergistic effects, C= 1 indicate additive effects, C41 indicate antagonistic effects. (c–e) Relative viable cell count is after 48 h treatment of
PDX samples with a combination of 0.2 μM tofacitinib and 0.3 μM selumetinib (c) or 0.2 μM trametinib (d) or a combination with 0.3 μM
tofacitinib and 0.13 μM ABT-199 (e). Data represents the average of three experiments± s.e.m. Significance was calculated using one-way
analysis of variance (ANOVA) and the Bonferroni correction. (****P⩽ 0.0001; ***P⩽ 0.001; nonsignificant (ns) P⩾ 0.05).
Phosphoproteomic screen of mutant JAK3
S Degryse et al
796
Leukemia (2018) 788 – 800
Inhibition of the P13K pathway revealed both high synergism
and high antagonism dependent on dosing schedules. Low
dosage of tofacitinib (up to 0.05 μM) in combination with
buparlisib elicited a highly antagonistic effect. However, signifi-
cant synergism (CIo0.1) was elicited through the use of
intermediate tofacitinib concentrations (0.2 μM) in combination
with high dose buparlisib (2.5 μM).
These initial screening matrices were then used to determine
optimal dosage regimens required to elicit a synergistic cytotoxi-
city in mutant JAK3-expressing cells and subsequently to be used
in experiments at fixed concentrations, alone and combined.
These fixed dose regimens significantly reduced proliferation
when in combination compared with single compound treat-
ments for both JAK3(M511I) and JAK3(L857Q) mutant-transformed
Ba/F3 cells (Figure 6b).
Synergistic effect of tofacitinib in combination with MEK or Bcl-2
inhibitors in JAK3 mutant PDX samples
To determine the preclinical efficacy of these drug combinations,
we next sought to determine the cytotoxic effect on primary
patient-derived T-ALL cells. Two T-ALL samples expressing a JAK3
(M511I) mutation (X1 1and 389E) and one sample that was JAK3
wild type (X10) were used (Supplementary Table 1). These patient
samples were initially expanded within NSG mice before collection
of the leukemic cells and immediately incubated ex vivo with our
optimized JAK3 pathway targeting regimens for 48 h (Figure 7a).
Tofacitinib in combination with the MEK and Bcl-2 inhibitors
were selected, as these combinations showed the most consistent
synergic effects over a wide range of concentrations. Synergy was
initially assessed and confirmed using the T-ALL X11 sample (JAK3
M511I) for the combination of tofacitinib and the MEK inhibitors,
selumetinib and trametinib, and the Bcl-2 inhibitor ABT-199.
Although most concentration combinations showed synergic
efficacy, some combinations of selumetinib and tofacitinib were
antagonistic revealing CI values up to 1.7. Notably, this antagon-
ism was only seen when combinations had the highest
concentration of tofacitinib (1.28 μM) (Figure 7b). Importantly,
the combination of trametinib and tofacitinib elicited cytotoxicity
with CI values ranging from o0.1 to 1, which is indicative of
highly synergistic efficacy. Furthermore, the most synergic
combination was elicited through the combination of low-dose
tofacitinib (0.01–0.04 μM) with low-dose trametinib concentrations
(0.015 μM) (Figure 7b). Targeting BCL2 using ABT-199 in combina-
tion with tofacitinib revealed high synergism. Low-dose tofacitinib
(0.08 μM) with low-dose ABT-199 (0.044 μM) resulted in a highly
synergistic CI value of o0.1 (Figure 7b).
Single synergistic dosage combinations determined using the
X11 sample were then used on the 389E (JAK3 M511I mutant
T-ALL sample) and X10 (JAK3 Wild-Type T-ALL sample) samples
(Figures 7c and d). The T-ALL cells expressing a JAK3(M511I)
mutation showed significantly reduced viability upon treatment
with the combination of the JAK selective inhibitor tofacitinib and
a MEK inhibitor selumetinib (Figure 7c) or trametinib (Figure 7d)
compared with single-compound treatment. Interestingly, T-ALL
cells 389E showed less sensitivity to JAK selective inhibition alone
(compared with X11), but synergy was still observed. The T-ALL
sample × 10, which expresses wild-type JAK3 (and also does not
harbor IL7R or JAK1 mutations), did not show any reduction in cell
viability after treatment with tofacitinib and/or selumetinib and
trametinib showing that the synergy is dependent on the
presence of a JAK3 mutation (Figures 7c and d).
The T-ALL samples were also treated with the Bcl-2 inhibitor
ABT-199 alone or in combination with tofacitinib. T-ALL samples with
JAK3 mutation were sensitive to both tofacitinib or ABT-199 alone,
and the combination of these drugs was more effective than each
drug separately. The T-ALL sample ×10 (JAK3 wild type) showed
reduced cell viability after treatment with the Bcl-2 inhibitor ABT-199,
but there was no additional reduction when combined with the JAK-
selective inhibitor tofacitinib (Figure 7e), indicating again that
synergy between tofacitinib and ABT-199 is only obtained in T-ALL
samples harboring a JAK3 mutation. Similar results were shown after
apoptosis staining using Annexin-V and propidium iodide. Treat-
ment of the T-ALL sample X11 with tofacitinib in combination with
selumetinib, trametinib or ABT-199 resulted in an increase in
Annexin-V+/propidium iodide+ cells compared with cells treated
with a single compound (Supplementary Figure S5).
In vivo combination treatment of patient-derived xenograft
sample carrying a JAK3 mutations leads to a significant decrease
in leukemia burden
Having established strong synergism between JAK3 and Bcl-2
inhibition, we moved to determine whether this could also be
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Figure 8. Combination treatment of mice xenografted with JAK3 (M511I) patient 389E. (a) Leukemia burden was followed on basis of human
CD45 expression in the peripheral blood. Treatment with vehicle (n= 7), ruxolitinib (40 mg/kg/day)(n= 7), ABT-199 (20 mg/kg/day; n= 7) or
ruxolitinib (40 mg/kg/day)+ABT-199 (20 mg/kg/day) (n= 8) was begun once CD45%42% and indicated with an arrow. Treatment continued
daily for 14 days. (b) End-stage assessment of human (h)CD45% in the peripheral blood. (c) End-stage assessment of human (h)CD45% in the
bone marrow. Significance was calculated using student t-test (***P⩽ 0.01; **P⩽ 0.05).
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observed in vivo. To this end, an in vivo patient-derived xenograft
model was established with T-ALL sample 389E that carries a JAK3
(M511I) mutation. For these studies, the JAK1-selective inhibitor
ruxolitinib was used due to its known side effect profile and
known efficacy in other hematological disorders27 in combination
with ABT-199. To accurately detect synergism, suboptimal
concentrations were used for ABT-199 (20 mg/kg/day/PO) and
ruxolitinib (40 mg/kg/day/PO), which were 70–80% reduced
compared with previously published studies when used as a
single agent.28,29 Leukemia burden was assessed by human CD45
expression in the peripheral blood at the beginning, midpoint and
end stage of the 14-day treatment phase. After 14 days, disease
burden was assessed in all mice and the combination treatment of
ruxolitinib and ABT-199 led to significant decrease of leukemia
cells in the peripheral blood and significantly less bone marrow
compared with vehicle, ABT-199-only or ruxolitinib-only treatment
(Figures 8a–c).
DISCUSSION
Although improved treatment and supportive care have led to a
better outcome for T-ALL patients, poor response to therapy and
relapse remain significant problems, especially in adult patients. In
addition, survivors continue to suffer long-term effects from
chemotherapy and in adults the rates of survival remain below
50%.30,31 Although there is no evidence that JAK3 mutations are
associated with a poor prognosis, this tyrosine kinase is an
attractive therapeutic target to help establish a more patient-
specific therapy.2,9 Precision therapeutic strategies targeting
recurring oncogene addicted cells along with the pathways that
cooperate in malignant cell growth offer treatment potentials that
are believed to have the greatest efficacy, while reducing side
effects.
Here we describe the first comprehensive analysis of phospho-
proteome signaling pathways regulated downstream of mutant
JAK3. We identified changes in phospho-peptides upon inhibition
of mutant JAK3 signaling, with the identification of proteins
involved in MAPK, PI3K/mTOR and apoptosis, and hitherto
unknown links to proteins involved RNA processing and
epigenetic regulation. It is known that JAK proteins are able to
phosphorylate the SH2 domain containing protein SHC1 that is
recruited to the cytokine receptor and in turn recruits the GRB2–
SOS complex. SOS is the guanosine nucleotide exchange factor for
RAS. Through RAS, the GRB2-SOS complex is able to activate the
canonical MAPK pathway.32 Both SHC1 and GAB2 phosphorylation
were significantly decreased upon inhibition of mutant JAK3
signaling. In addition to the RAS/MAPK pathway, the PI3K pathway
has also been shown to have an important role downstream of the
JAK kinases. Sharfe et al.5 showed that JAK3 was able to interact
with the p85 subunit of PI3K upon IL7 stimulation and
subsequently induced phosphorylation of this p85 subunit. PI3K
also interacts with the GAB2 adaptor protein, which indicates a
link between PI3K and MAPK activation.33
A number of candidate proteins found to be directly down-
stream of mutant JAK3 have already been found to have
important roles either in the pathogenesis of T-ALL or cancer in
general. We have recently described a link between mutations in
proteins involved in epigenetic regulation such as the PRC2
complex and mutations in the IL7R/JAK3 signaling pathway.2 Here
we show phosphoproteomic data linking mutant JAK3 signaling
with proteins implicated in epigenetic regulation. In the current
work, we describe an increased phosphorylation of KDM2A upon
inhibition of mutant JAK3 signaling. KDM2A is a histone
demethylase that specifically demethylates lysine-36 of histone
3. Increased expression levels of KDM2A promotes tumor cell
growth and migration in gastric cancer34 but there are currently
no reports on how the phosphorylation status of KDM2A
threonine 713 (T713) regulates its activity. However, KDM2A is
phosphorylated at threonine 632 (T632) following DNA damage
and largely abrogates the chromatin-binding capacity of
KDM2A.35 We also reveal reduced phosphorylation of the DNA
methyltransferase family member DNMT1 upon inhibition of
mutant JAK3 signaling (Figure 4). DNMT1 is required to maintain
the methylation of the entire genome and altered expression has
been observed in a range of cancers including lymphoma, breast,
colon, liver, pancreas and esophagus cancer.36 For both KDM2A
and DNMT1, it will be important now to determine the role of
these phosphorylation sites in regulating protein function and
their role in T-ALL.
One of the more surprising links we found downstream mutant
JAK3 signaling was RNA metabolism including proteins involved in
mRNA stability, splicing and degradation. There were significant
decreased phosphorylation changes upon inhibition of JAK3 in
RRP1B, NCBP1, SERBP1, YBX3, ATXN2L, U2SURP, HNRNPM,
HNRNPK and GTPBP1, and significant increased phosphorylation
changes upon inhibition of JAK3 in CMTR1, RNMT, ZC3H13, SF3B1,
PNN, CASC3 and SF1. Of these candidate proteins, a number
already have potential roles in cancer. RRP1B expression levels can
predict patient outcome in breast cancer and can regulate histone
methylation.37 SERBP1 has been found to be significantly
upregulated in CD34+ CML cases compared with control C34+
cells.38 Significant hypermethylation of the YBX3 promoter to
downregulate its mRNA expression has been found in AML.39
HNRNPM has been found to promote cancer metastasis by
regulating alternative splicing.40 Depletion of RNMT has been
described to effectively and specifically inhibits cancer cell growth
and cell invasive capacities in different types of cancer.21 SRRM1
has been shown to regulate splicing of the CD44 protein41 and the
identification of different residues that increase and decrease in
phosphorylation status may indicate a functional switch for this
protein. Finally, SF3B1 is recurrently mutated in MDS and CLL,20,42
and SF3B1 inhibitors are in preclinical development for the
treatment of cancer and therefore may have potential indications
in combination with JAK3 inhibitors in T-ALL.
To this end, phosphoproteomic profile provided a list of
pathways that could be targeted by small molecular inhibitors in
combination of JAK3 inhibitors. We show that the combined
inhibition of JAK3 signaling with inhibitors targeting PI3K, MEK or
BCL2 resulted in a synergistic cytotoxic effect in Ba/F3 samples
transformed by JAK3 mutants and primary T-ALL patient samples
carrying JAK3 mutations. This synergistic effect was selective for
JAK3-mutated T-ALL samples, as no synergy was observed in the
T-ALL sample that was wild type for JAK3. We also tested the
combination of ruxolitinib with ABT-199 in vivo and this also
resulted in a significant decrease in leukemia burden, suggesting
this combinational would be an effective treatment strategy in
patients with a JAk3 mutation. Recently, Canté-Barrett et al.43
showed that inhibiting both the MEK and PI3K-AKT pathways
synergistically prevents the proliferation of Ba/F3 cells expressing
JAK3 mutants. Furthermore, combined inhibition of MEK and PI3K/
AKT was cytotoxic to four primary T-ALL patient samples, which
carried a JAK3 mutation. It has also been shown that immature
T-ALL patients with high levels of BCL2 were sensitive to ABT-199
as a single agent.44 We have now extended this observation to
take into account the JAK3 mutational status and tested the
inhibitory effects of ABT-199 in combination with tofacitinib, a JAK
selective inhibitor and show that this combination is highly
effective in causing cytotoxicity for T-ALL cells. It is important to
note that for some concentrations combinations of MEK or BCL2
inhibitors with the JAK inhibitor tofacitinib resulted in an
antagonistic or additive effect rather than a synergistic effect.
This highlights the importance of identifying the optimal
treatment dose for patients in order to obtain maximal synergy.
In summary, this study has characterized signaling downstream
of mutant JAK3 showing constitutive activation of proteins
involved in cell cycle, translation, apoptosis, MAPK and PI3K/AKT
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pathways and epigenetic regulation. Through the use of primary
T-ALL samples we show synergistic inhibition by combining JAK-
selective inhibitors with MEK, PI3K and BCL2 inhibitors. Together,
our research gives the incentive to further explore the use of JAK
inhibitors in combination with MEK or BCL2 inhibitors in order to
optimize current treatment regimes.
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